Fierce Healthcare Fundraising Tracker—Cancer-testing startup Artera banks $90M; ‘Radiology in a Box’ developer OXOS Medical nabs $23M
The maker of AI-based prognostic cancer tests is led by its flagship offering ArteraAI Prostate Test. The test is at the fore [...]
ArteraAI Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI
ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launched publicly [...]
MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer
Jessica Nye from Cancer Therapy Advisor discusses key findings, presented by Daniel Spratt, MD at ASCO GU 2023, demonstrating [...]
Multimodal AI Biomarker May Help Personalize Decision-Making in High-Risk Prostate Cancer
Mark Leiser from HemOnc Today discusses results from ArteraAI’s prognostic MMAI model that were presented by Daniel Spratt, M [...]
Our science was presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18.
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate C [...]
How AI can support the American Cancer Society’s IMPACT Initiative
Andre Esteva, Co-founder and CEO of ArteraAI, discusses how AI can support the ACS’ IMPACT initiative and other possibilities [...]
An Introduction to ArteraAI’s Cloud Infrastructure
Introduction ArteraAI was founded on the idea that cutting edge technology can be used to completely transform the medical fi [...]